R H Demling1, D P Orgill. 1. The Burn Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Abstract
PURPOSE:Severe burn injury leads to marked catabolism and decreased lean mass, which can impair healing. Anabolic agents can attenuate net catabolism. Our purpose was to determine whether the testosterone analog, oxandrolone, given during the acute post burn period decreased the degree of nitrogen loss and loss of body weight while also increasing the healing rate of a skin donor site. MATERIALS AND METHODS: Patients with burns between 40% and 70% of body surface were studied. A randomized double-blinded placebo-controlled study design was used. Patients were given oxandrolone 20 mg/day (n = 11) or a placebo 20 mg/day (n = 9) beginning between days 2 and 3 post burn. Net nitrogen balance and the healing time of a standardized donor site were measured. Patients were monitored until transferred to a burn rehabilitation facility, an average time period of 33 +/- 9 days. RESULTS:Mean burn size was 49 +/- 8% for placebo and 53 +/- 9% of total body surface for the oxandrolone group. Smoke inhalation was present in approximately 50% of patients in both groups. All patients survived the burn injury. Net weight loss was 8 +/- 3.1 kg in the placebo group compared with 3 +/- 1.9 kg in the oxandrolone group, a statistically significant decrease. Net daily nitrogen loss over a 3-week period (days 7 to 28) was 13 +/- 4 g in placebo treated compared with 4 +/- 1.9 g for the oxandrolone group, a statistically significant decrease. The healing time of a standardized donor site, decreased from the placebo group value of 13 +/- 3 days to 9 +/- 2 days for oxandrolone treated patients, a significant improvement. No major liver dysfunction, or other complication attributable to an anabolic steroid was seen in either group. CONCLUSION: We found the anabolic agent, oxandrolone, significantly decreased weight loss and net nitrogen loss and increased donor site wound healing compared with placebo controls. We noted no complications with the use of oxandrolone.
RCT Entities:
PURPOSE: Severe burn injury leads to marked catabolism and decreased lean mass, which can impair healing. Anabolic agents can attenuate net catabolism. Our purpose was to determine whether the testosterone analog, oxandrolone, given during the acute post burn period decreased the degree of nitrogen loss and loss of body weight while also increasing the healing rate of a skin donor site. MATERIALS AND METHODS:Patients with burns between 40% and 70% of body surface were studied. A randomized double-blinded placebo-controlled study design was used. Patients were given oxandrolone 20 mg/day (n = 11) or a placebo 20 mg/day (n = 9) beginning between days 2 and 3 post burn. Net nitrogen balance and the healing time of a standardized donor site were measured. Patients were monitored until transferred to a burn rehabilitation facility, an average time period of 33 +/- 9 days. RESULTS: Mean burn size was 49 +/- 8% for placebo and 53 +/- 9% of total body surface for the oxandrolone group. Smoke inhalation was present in approximately 50% of patients in both groups. All patients survived the burn injury. Net weight loss was 8 +/- 3.1 kg in the placebo group compared with 3 +/- 1.9 kg in the oxandrolone group, a statistically significant decrease. Net daily nitrogen loss over a 3-week period (days 7 to 28) was 13 +/- 4 g in placebo treated compared with 4 +/- 1.9 g for the oxandrolone group, a statistically significant decrease. The healing time of a standardized donor site, decreased from the placebo group value of 13 +/- 3 days to 9 +/- 2 days for oxandrolone treated patients, a significant improvement. No major liver dysfunction, or other complication attributable to an anabolic steroid was seen in either group. CONCLUSION: We found the anabolic agent, oxandrolone, significantly decreased weight loss and net nitrogen loss and increased donor site wound healing compared with placebo controls. We noted no complications with the use of oxandrolone.
Authors: Jakob L Vingren; William J Kraemer; Nicholas A Ratamess; Jeffrey M Anderson; Jeff S Volek; Carl M Maresh Journal: Sports Med Date: 2010-12-01 Impact factor: 11.136
Authors: Jeremy G Fisher; Eric A Sparks; Faraz A Khan; Jamin L Alexander; Lisa A Asaro; David Wypij; Michael Gaies; Biren P Modi; Christopher Duggan; Michael S D Agus; Yong-Ming Yu; Tom Jaksic Journal: Pediatr Crit Care Med Date: 2015-07 Impact factor: 3.624
Authors: Michael S D Agus; Patrick J Javid; Hannah G Piper; David Wypij; Christopher P Duggan; Daniel P Ryan; Tom Jaksic Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: Marc G Jeschke; Celeste C Finnerty; Oscar E Suman; Gabriela Kulp; Ronald P Mlcak; David N Herndon Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Eileen M Bulger; Gregory J Jurkovich; Catherine L Farver; Patricia Klotz; Ronald V Maier Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Tam N Pham; Matthew B Klein; Nicole S Gibran; Brett D Arnoldo; Richard L Gamelli; Geoffrey M Silver; Marc G Jeschke; Celeste C Finnerty; Ronald G Tompkins; David N Herndon Journal: J Burn Care Res Date: 2008 Nov-Dec Impact factor: 1.845